Page History

...

For RSNA 2018, the application was re-designed to promote more comprehensive data collection and increased community participation. Participants were instructed to identify all metastatic disease and provide details regarding image quality, lesion location and characteristics. To provide additional incentives for participation, we improved the system by adding gamification features (e.g., reward badges), and created a leaderboard to display participant standings.  The amount of data being annotated was also significantly increased to include CT scans from 324 patients spanning 13 TCIA collections:  Anti-PD-1_Lung,  Anti-PD-1_MELANOMA,  The Clinical Proteomic Tumor Analysis Consortium Clear Cell Renal Cell Carcinoma Collection (CPTAC-CCRCC),  The Clinical Proteomic Tumor Analysis Consortium Glioblastoma Multiforme Collection (CPTAC-GBM),  The Clinical Proteomic Tumor Analysis Consortium Head and Neck Squamous Cell Carcinoma Collection (CPTAC-HNSCC),  The Clinical Proteomic Tumor Analysis Consortium Pancreatic Ductal Adenocarcinoma Collection (CPTAC-PDA),  The Clinical Proteomic Tumor Analysis Consortium Uterine Corpus Endometrial Carcinoma Collection (CPTAC-UCEC),  NSCLC Radiogenomics,  The Cancer Genome Atlas Urothelial Bladder Carcinoma Collection (TCGA-BLCA),  The Cancer Genome Atlas Colon Adenocarcinoma Collection (TCGA-COAD),  The Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma Collection (TCGA-HNSC),  The Cancer Genome Atlas Lung Squamous Cell Carcinoma Collection (TCGA-LUSC),  The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma Collection (TCGA-UCEC).  During RSNA 2018, 4756 bi-directional measurements were obtained compared to 2345 uni-dimensional measurements in 2017. Of the 4756 measurements, 65% of the lesions were annotated with location information. The data is being released in DICOM Structured Report and CSV formats for analysis by the community. The application is available on GitHub https://github.com/crowds-cure/cancer .

...

...